Greenwood Capital Associates’s GSK GSK Stock Holding History

Greenwood Capital Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-51,289	Closed	-$1.97M	–	244
2024 Q2	$1.97M	Sell	51,289 -1,911	-4%	-$80.4K	0.26%	91
2024 Q1	$2.28M	Sell	53,200 -3,076	-5%	-$127K	0.3%	82
2023 Q4	$2.09M	Sell	56,276 -742	-1%	-$26.6K	0.27%	85
2023 Q3	$2.07M	Buy	57,018 +709	+1%	+$25.2K	0.3%	84
2023 Q2	$2.01M	Sell	56,309 -378	-0.7%	-$13.6K	0.28%	83
2023 Q1	$2.02M	Buy	56,687 +4,491	+9%	+$157K	0.29%	86
2022 Q4	$1.83M	Buy	52,196 +720	+1%	+$24K	0.3%	73
2022 Q3	$1.51M	Buy	51,476 +23,764	+86%	+$901K	0.26%	84
2022 Q2	$1.51M	Buy	27,712 +2,122	+8%	+$117K	0.24%	80
2022 Q1	$1.39M	Buy	25,590 +4,915	+24%	+$267K	0.37%	48
2021 Q4	$1.14M	Buy	20,675 +2,893	+16%	+$150K	0.16%	110
2021 Q3	$849K	Buy	17,782 +6,096	+52%	+$306K	0.13%	128
2021 Q2	$582K	Buy	+11,686	New	+$562K	0.09%	171

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Greenwood Capital Associates's GSK Position: Q3 2024 in Review

Greenwood Capital Associates sold out of GSK (GSK) in Q3 2024, closing a stake of 51,289 shares — an estimated $1.97M sold.

Greenwood Capital Associates first reported a position in GSK in Q2 2021 and held it in 13 quarters. The position peaked at $2.28M in Q1 2024. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

Greenwood Capital Associates reported no remaining GSK position as of Q3 2024 after selling out during the quarter.
Greenwood Capital Associates sold 51,289 GSK shares in Q3 2024, an estimated $1.97M.
Greenwood Capital Associates first reported a position in GSK in Q2 2021 and held it in 13 quarters.
Greenwood Capital Associates's GSK position peaked at $2.28M in Q1 2024.
899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on Greenwood Capital Associates's 13F filing for Q3 2024, filed 30 Oct 2024.